NuCana (NASDAQ:NCNA) Trading Down 6.5% – Here’s What Happened

NuCana plc (NASDAQ:NCNA)’s stock price traded down 6.5% during trading on Thursday . The stock traded as low as $1.14 and last traded at $1.15. 118,431 shares traded hands during mid-day trading, an increase of 6% from the average session volume of 111,346 shares. The stock had previously closed at $1.23.

NuCana Stock Down 1.7 %

The company’s fifty day simple moving average is $1.32 and its two-hundred day simple moving average is $2.62. The company has a market capitalization of $2.99 million, a price-to-earnings ratio of -0.11 and a beta of 0.97.

Institutional Investors Weigh In On NuCana

A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc bought a new position in NuCana plc (NASDAQ:NCNA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned 0.57% of NuCana at the end of the most recent quarter. Institutional investors and hedge funds own 44.00% of the company’s stock.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.